Johnson & Johnson (NYS: JNJ) reported earnings yesterday. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Johnson & Johnson met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share grew.


Gross margins dropped, operating margins dropped, net margins increased.

Revenue details
Johnson & Johnson logged revenue of $16.14 billion. The 16 analysts polled by S&P Capital IQ predicted revenue of $16.28 billion on the same basis. GAAP reported sales were 0.2% lower than the prior-year quarter's $16.17 billion.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $1.37. The 21 earnings estimates compiled by S&P Capital IQ averaged $1.35 per share on the same basis. GAAP EPS of $1.41 for Q1 were 13% higher than the prior-year quarter's $1.25 per share.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 69.5%, 100 basis points worse than the prior-year quarter. Operating margin was 28.3%, 10 basis points worse than the prior-year quarter. Net margin was 24.2%, 270 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $16.68 billion. On the bottom line, the average EPS estimate is $1.30.

Next year's average estimate for revenue is $66.71 billion. The average EPS estimate is $5.11.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 13,509 members out of 13,995 rating the stock outperform, and 487 members rating it underperform. Among 3,164 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 3,094 give Johnson & Johnson a green thumbs-up, and 70 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Johnson & Johnson is outperform, with an average price target of $71.15.

The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Johnson & Johnson the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

At the time this article was published Seth Jayson owned shares of the following at the time of publication: Johnson & Johnson. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Behavioral Finance

Why do investors make the decisions that they do?

View Course »

Investment Strategies

What's your investing game plan?

View Course »

Add a Comment

*0 / 3000 Character Maximum